Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,600 Shares

Key Points

• Director Jason Rhodes sold 11,600 shares on May 5 at an average price of $18.03 under a pre‑arranged Rule 10b5‑1 plan, cutting his holding by 58% to 8,390 shares (disclosed in an SEC Form 4).
• Market and analyst context: DYN traded around $18.84 (market cap ≈ $3.11B) and has a consensus "Moderate Buy" from analysts with an average price target of $35.14.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,600 shares of the firm's stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $18.03, for a total transaction of $209,148.00. Following the completion of the transaction, the director directly owned 8,390 shares in the company, valued at approximately $151,271.70. The trade was a 58.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded up $1.37 during trading hours on Wednesday, hitting $18.84. 1,720,199 shares of the stock traded hands, compared to its average volume of 2,090,953. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -5.32 and a beta of 1.08. The stock has a 50 day moving average price of $17.94 and a 200 day moving average price of $18.56.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Dyne Therapeutics by 9.0% in the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company's stock worth $42,570,000 after buying an additional 278,466 shares in the last quarter. Aberdeen Group plc lifted its holdings in shares of Dyne Therapeutics by 15.0% in the third quarter. Aberdeen Group plc now owns 556,733 shares of the company's stock worth $7,043,000 after buying an additional 72,770 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Dyne Therapeutics by 27.6% in the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company's stock worth $123,469,000 after buying an additional 2,109,257 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth $5,191,000. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Dyne Therapeutics by 93.4% in the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company's stock worth $2,697,000 after buying an additional 102,963 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. HC Wainwright lowered their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 3rd. Chardan Capital reaffirmed a "buy" rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Dyne Therapeutics in a report on Monday, March 9th. JPMorgan Chase & Co. lowered their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating on the stock in a report on Tuesday, January 20th. Finally, Morgan Stanley lowered their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating on the stock in a report on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $35.14.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.